Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Zevra Therapeutics (ZVRA) Gains from Sales and Divestitures: 2024

Historic Gains from Sales and Divestitures for Zevra Therapeutics (ZVRA) over the last 1 years, with Dec 2024 value amounting to $765,945.

  • Zevra Therapeutics' Gains from Sales and Divestitures was N/A to $765,945 in Q4 2024 from the same period last year, while for Dec 2024 it was $765,945, marking a year-over-year change of. This contributed to the annual value of $765,945 for FY2024, which is N/A change from last year.
  • Zevra Therapeutics' Gains from Sales and Divestitures amounted to $765,945 in FY2024.
  • Zevra Therapeutics' 5-year Gains from Sales and Divestitures high stood at $765,945 for FY2024, and its period low was $765,945 during FY2024.
  • In the last 1 years, Zevra Therapeutics' Gains from Sales and Divestitures had a median value of $765,945 in 2024 and averaged $765,945.